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Abstract 
 
In recent years, cancer genome sequencing and other high-throughput studies of cancer 
genomes have generated many notable discoveries. In this review, Novel genomic 
alteration mechanisms, such as chromothripsis (chromosomal crisis) and kataegis 
(mutation storms), and their implications for cancer are discussed. Genomic alterations 
spur cancer genome evolution. Thus, the relationship between cancer clonal evolution 
and cancer stems cells is commented. The key question in cancer biology concerns how 
these genomic alterations support cancer development and metastasis in the context of 
biological functioning. Thus far, efforts such as pathway analysis have improved the 
understanding of the functional contributions of genetic mutations and DNA copy 
number variations to cancer development, progression and metastasis. However, the 
known pathways correspond to a small fraction, plausibly 5-10%, of somatic mutations 
and genes with an altered copy number. To develop a comprehensive understanding of 
the function of these genomic alterations in cancer, an integrative network framework is 
proposed and discussed. Finally, the challenges and the directions of studying cancer 
omic data using an integrative network approach are commented. 
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1. Introduction  
    Because of the ongoing development of new, fast, and inexpensive DNA sequencing 
technologies, the cost of genome sequencing technology has rapidly declined. Eventually, 
genome sequencing technology may allow doctors to decoding the entire genetic code of 
a patient disease sample in a clinical setting. Cancer is rooted in genetic and epigenetic 
alterations, which are either inherited or acquired (i.e., mutated or methylated) during our 
lives. Cancer genomes contain two classes of mutations: driver mutations, which are 
positively selected because they are essential for tumor growth and development, and 
passenger mutations, which are not subject to selection because they do not offer a 
growth advantage. Positive selection indicative of driver mutations is evidenced by a 
higher probability than by chance of amino acid-changing nonsynonymous mutations to 
synonymous mutations that do not involve amino acid changes. 
 
     However, we are still no closer to uncovering the molecular underpinnings of the 
disease. If we could catalog cancer driver-mutating genes, we could link these genes to 
biological pathways, biological processes and cellular networks. Cancer genome 
sequencing and omic studies will improve the understanding of the genetic/epigenetic 
underpinnings of major types and subtypes of human cancer, thus generating new 
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insights concerning how to address and to manage cancer in clinics. These studies will 
eventually enable more personalized treatments that will improve patient care. 
 
     Significant effort has focused on compressive omic analysis, including genome 
sequencing, SNPs profiling, gene expression, epigenetic changes and proteomic profiling 
of major tumor types. These efforts represent a decade-long program that has aimed to 
generate high-quality omic data on more than 25,000 tumors for up to 50 types of cancer 
of clinical and societal importance. Three major organizations, the Wellcome Trust 
Sanger Institute in the United Kingdom, the Cancer Genome Atlas (TCGA) in the United 
States and the International Cancer Genome Consortium (ICGC) [1] in Canada, have 
advanced this program. Furthermore, several countries are working on this project, and 
the ICGC is collecting, merging and managing all of the data. In fact, the sequencing of 
25,000 tumors is being performed around the world in 40 projects focused on the bladder, 
the blood, the bone, the brain, the breast, the cervix, the colon, the head and the neck, the 
kidney, the liver, the lung, the oral cavity, the ovary, the pancreas, the prostate, the 
rectum, the skin, the soft tissues, the stomach, and the uterus. The ICGC has collected 
omic data on more than 3,500 tumors. 
 
    Among these efforts, St. Jude Children's Research Hospital took an initiative to make 
cancer genome information freely accessible to the global scientific community at 
www.ebi.ac.uk/ega/organisations/EGAO00000000046. [2] This site mainly includes the 
genome sequences (entire genome sequencing with up to a 30-fold coverage) for matched 
sets of normal and tumor tissue samples from pediatric cancer patients. It is expected to 
sequence more than 1,200 genomes by the end of 2012. It represents the world's greatest 
effort and investment to understand the genetic origins of childhood cancers and is the 
first major privately funded human genome sequencing project to share its data as soon as 
they become available. Table 1 summarizes the major completed genome sequencing 
efforts (i.e., at least 20 genomes have been sequenced in each study), most of which were  
published in 2012. In terms of cancer genome sequencing, 2012 signals the start of a 
significant increase in the amount of cancer genome sequencing data.  
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   These efforts have generated several notable insights, including new genomic alteration 
mechanisms, the tracing and deciphering of cancer genome evolution and the dissection 
of tumor subclones. 
 
2. Cancer genome sequencing uncovered unexpected genomic alteration 
mechanisms 
2.1. Chromothripsis 
    Traditionally, cancer has been believed to develop gradually in a steady and stepwise 
progression. It often takes years to accumulate the multiple mutations to facilitate 
cancer's aggressive growth. In fact, most cancers undergo phases of abnormal tissue 
growth before developing into malignant tumors. However, recent analyses of tumor 
genomes revealed different patterns of genomic alteration mechanisms. One mechanism, 
“chromothripsis” [3], is a process by which a genome shatters into hundreds of fragments 
for one chromosome or several chromosomes in a single cellular catastrophe, and the 
DNA repair machinery then recombines the fragments in a highly erroneous order. This 
process generates gene amplifications/deletions on a massive scale. This mechanism 
suggests that a chromothripsis (also called a chromosomal crisis) can generate multiple 
oncogenes or tumor suppressors in a single event. Chromosomal crises have been 
observed across all common cancers at an incidence rate of 1/40 but are more common in 
bone cancers, with an incidence rate of 20% [3]. Chromothripses have been observed in 
other studies, although at a similarly low incidence rate (2%-4%) [4, 5]. 
    It has been suggested that  P53 mutation may trigger a chromothripsis. However, a P53 
mutation is very common in cancer. An intriguing question concerns whether a 
chromosomal crisis occurs often or occasionally in the human body’s cells. Notably, 
some cells that undergo a chromosomal crisis are able not only to survive but also to 
emerge with a genomic landscape that grants a selective advantage to the clone, thus 
promoting cancer development. Because a chromosomal crisis induces many dramatic 
genomic changes, we expect that a fraction of the genetic alterations are harmful to cells’ 
survival. Should this expectation be accurate, many cells undergoing a chromosomal 
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crisis could die, and we would be unaware of the occurrence. Another possibility is that 
tumor cells with many dramatic genetic alterations induced by a chromosomal crisis are 
so weak that they can be eliminated by tumor microenvironments. These factors may 
explain the extremely low rate of chromothripsis in tumors. Comparing the 
microenvironments of the tumors that have or do not have chromothripsis might offer 
insight regarding this point. The survival outcomes of the patients with chromothripsis-
derived and patients with non-chromothripsis-derived tumors need to be reviewed. 
2.2. Kataegis 
     Chromothripsis refers to a new oncogenic mechanism that operates on a global level; 
that is, it occurs in one chromosome or in several chromosomes. Another new mutation 
mechanism has been found to operate locally, generating large numbers of mutations (or 
hotspots of hypermutations) in small regions of the genome; this process has been termed 
'kataegis' (from the Greek word for thunderstorm) [6]. Compared with chromothripsis, 
which occurs at a rate of 1/40 in cancer genomes, kataegis is remarkably common, 
occurring at a rate of 13/21 in breast cancer genomes. Kataegis most likely causes 
mutations to occur at one time rather than accumulating in a step-wise fashion. Kataegis 
is observed when a large number of substitution mutations occur simultaneously and 
extremely close to one another in a region of the genome [6]. Therefore, kataegis can be 
identified as distinguishing mutational patterns that often co-occur with large-scale 
rearrangements. Kataegis has been described as most likely occurring at one time; 
however, certain regions of the genome may mutate repeatedly during tumor evolution. If 
this possibility is proven, the affected regions are extended due to mutations between 
different subclones. Whether such extended mutation profiles are found in these genome 
regions requires further examination. 
     These mutation mechanisms indicate that internal factors, such as genome 
rearrangement, may contribute some types of genetic mutations and that some regions of 
cancer genomes are more likely to mutate than others. Several questions remain. The first 
question concerns (1) whether kataegis occurs once or repeatedly in different subclones. 
Based on the results, kataegis most likely occurs in different subclones across the tumor’s 
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evolution; however, this conclusion need to be confirmed. The remaining questions 
concern (2) whether the genomic alterations derived from kataegis or chromothripsis are 
enriched with cancer drivers; (3) whether kataegis or chromothripsis results from 
specifically defective internal cellular machinery or certain combinatory patterns of 
existing mutations or from other epigenetic alterations; (4) whether kataegis-derived 
cancer genomes are more aggressive than the tumors derived from other genomic 
alteration mechanisms; and (5) whether the DNA copy number change represents an 
important genetic alteration in cancer cells. A series of chromothripses might convert a 
cell into a cancer cell quickly. However, these cells may not mutate but rather undergo 
many copy number changes. Further investigations of these novel genomic alteration 
mechanisms may deepen the understanding of factors influencing these mutations/copy 
number variations and cancer development. Nevertheless, early mutations, copy number 
changes or alterations of chromosomal structures caused by other factors, such as 
smoking, sunlight, or stress, may be conducive to kataegis or chromothripsis. 
3. Genomic alterations and cancer genome sequencing 
3.1. Deciphering cancer genomic alterations in an evolutionary context 
     Tumors are widely known to be heterogeneous. Therefore, a tumor is often expected 
to comprise a set of clones of cancer cells. Understanding the mechanisms that cause 
cancer requires comprehensive insight into the processes underlying cancer genetics. To 
obtain this information, the Sanger group sequenced 21 breast cancer genomes, 
catalogued their mutations and attempted to trace the evolution of cancer mutation 
profiles between different subclones in the context of timing [7]. Using appropriate 
bioinformatic approaches, they were able to uncover the genetic mutation marks and the 
inscribed record of the latter’s emergence over time, thus enabling the divergence of a 
cell in forming the various clones to be traced. 
     Cancer mutational processes evolve over a tumor’s lifespan. Each time a gene is 
mutated in a cell, the mutation event encrypts a distinctive stamp inscribed in its genome. 
Such a distinctive stamp can be considered a mutation signature or a distinctive mark on 
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the genome. From a historical perspective, an archaeological history of mutations results 
from the accumulations of marks upon one another. Therefore, collecting, cataloguing 
and sorting the orders of these marks allow the cancer's life history to be deciphered. 
Cells in a single subclone possess an identical genetic mutation profile. The cells in late-
occurring subclones add new mutations to the genetic mutation profiles of the early 
subclones. Only a mutation causes a clone to dramatically expand, after which the clone 
constitutes the tumor’s dominant population and the tumor grows large enough to be 
diagnosed. During this process, the history of the genetic mutations and the emergence 
and the expansion of the new clone is imprinted upon the cancer genome. Therefore, 
these genetic mutation profiles can be used to build an evolutionary tree of subclones. 
This analysis allows the tracing of the occurrence of a new mutation profile, the 
biological processes involved in each mutation profile or subclone, and the proportion of 
each subclone present in the tumors. The study showed that as the mutations, or genetic 
marks, accumulate in a cell, the corresponding changes caused the cancer to diverge into 
different clones [7]. The emergence of different subclones occurred in all of the examined 
cancer genomes. This analysis suggests that when a new subclone has grown sufficiently 
to constitute the dominant population of cancer cells (i.e., more than 50% of tumor cells), 
the tumor becomes clinically detectable. The genetic mutation profiles of subclones and 
dominant subclones differ markedly, implying that the dominant subclone may require a 
significant amount of time to develop. 
     This study has several implications. First, it confirms that a tumor contains many 
subclones; thus, the heterogeneity can be sampled by sequencing, as shown in Gerlinger 
et al. [7]. Second, the study suggests that a cancer patient may benefit from the use of 
combinatory drugs for different subclones. One perspective is that treatment may proceed 
by targeting the early clones because their mutation profiles are identical to those of the 
late subclones [8]. However, this approach might not work well. The late subclones, 
particularly the dominant subclones, acquire new traits for cell proliferation and survival. 
These new traits could grant the late subclones “new” survival capabilities, thus implying 
that the ‘drug targets’ for the early subclones are unsuitable for the late subclones. 
However, subclones [9] can successfully be dissected from tumors, and the RNA-seq or 
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sequencing analysis of these subclones can be performed [10]. Profiling these subclones 
helps to identify drug targets for each subclone. Third, each cancer appears to be 
generated by a distinct combination of mutational processes. Fourth, the study confirms 
the prediction that transforming a normal cell to a cancer cell is a lengthy process that has 
been shown to last 10 years [11]. This fact supports the search for mutation signatures or 
molecular biomarkers for early diagnosis and the possibility of personalized early 
preventions to potential cancer patients. 
3.2. Which subclone contains the cancer stem cell?  
    Although many implications have been found from deciphering cancer genomes, a key 
question remains: can we identify or infer which subclone contains the cancer stem cell?  
     The cancer stem cell hypothesis suggests that tumors are organized into aberrant cell 
hierarchies. In such a hierarchy, a cancer stem cell capable of replicating indefinitely is 
the parent cell that generates differentiated daughter cells with a limited capacity to 
proliferate. If proven for a tumor, this hypothesis suggests that cancer is curable if drugs 
are available to kill cancer stem cells. Recently, three studies have provided the first 
evidence that cancer stem cells exist [12]. These studies have demonstrated that cancer 
stem cells reproduce cancer cells when the tumor is extinguished by anticancer drugs, a 
result that applies to benign and malignant tumors.  
     These results suggest that cancer stems cells are inherently capable of propagating 
genetic or epigenetic alterations throughout a tumor and driving cancer evolution. The 
cancer stem cells constitute the stem of tumor cell production. During a cancer’s 
evolution, a certain genetic mutation profile may define cancer stem cell subclones. The 
parental subclones of the cancer stem cell subclone are non-stem cells, thus indicating 
that genetic/epigenetic changes could convert a non-stem cell into a cancer stem cell. 
Such a stem cell produces many daughter cells that may further evolve into diversified 
cancer cells. If this process occurs, then the dominant subclones of the tumors would not 
be cancer stem cells but would emerge from cancer stem cells.  
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     Thus, many questions remain. First, should every tumor contain a subset of cancer 
stem cells? All tumors may not contain cancer stem cells, for example, if a 
chromothripsis occurs to generate enough fitting combinations of mutations to generate a 
new subclone capable of becoming dominant in a tumor. However, generally, sustaining 
the cancer’s evolution requires generating enough cancer cells using cancer stem cells. In 
this case, a cancer stem cell must evolve and be defined by a set of mutations. Second, if 
a cancer stem cell must exist in a tumor, what are the characteristics of its genetic 
mutation profiles? The evolution of cancer genomes implies that a cancer stem cell 
subclone should be an early subclone in the history of the tumor’s development. We 
assume that the cancer stem cell subclone generates new cells but at a limited and slow 
rate because of the microenvironment’s unfavorable conditions. These daughter cells are 
further mutated and generate new subclones.  
     This hypothesis is supported by the discoveries of Driessens et al. [12-14] and Chen et 
al. [13] that show that the cellular organization of early (precancerous) skin and intestinal 
tumors are composed of both stem cells and non-stem cells. Furthermore, Driessens et al. 
observed that progression to cancer in benign skin tumors is associated with an increased 
cancer stem cell population. They found that every cancer stem cell within a tumor is 
equally probable of clonally expanding or dying, possibly even in the absence of new 
mutations, thus suggesting that a cancer stem cell subclone most likely occurs in an early 
stage of cancer development (Fig 1). 
     The most important finding from the above discussion is that subclonal diversity in 
cancer genomes may be dissected. To treat cancer more efficiently requires the dissection 
of not only the dominant subclones but also the minor subclones, which are among the 
top subclones in the hierarchy and most likely cancer stem cells. The key challenges are 
determining the functions of the mutations in these subclones and linking these mutations 
to drug targets for each subclone and, subsequently, identifying mutational signatures as 
diagnostic tools that predict the early development of cancer. 
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4. The functional understanding of genomic alterations in cancer genomes at a 
systems level 
 
    As discussed above, in recent years, sequencing efforts have generated many genomic 
alterations of cancer. Although some important insights, such as new genomic alteration 
mechanisms, cancer genome evolution, and clonal dissection, have been gleaned from the 
corresponding data, a lack of frameworks and tools nevertheless persists with respect to 
how genomic alterations drive cancer evolution, clonal expansion, and cancer 
development and metastasis. Understanding these processes requires investigating the 
function of these genomic alterations. However, currently, the greatest challenge is 
understanding the functions of driver mutations in cancer genomes. On average, several 
hundred driver mutations have been catalogued from each tumor, but interpreting these 
mutations is inefficient, thus limiting the understanding of why and how these mutation 
genes work. Most current cancer genome sequencing work has mapped the mutations 
onto biological pathways, including signaling pathways. 
 
     A biological pathway contains a set of linear relationships between genes or proteins 
and is an important model to describe biological relationships. From an abstract 
perspective, a pathway is a model that represents humans’ efforts to explore, describe, 
and organize biological relationships in cells [15]. Such efforts allow us to further 
understand biological systems and to predict cell behaviors. However, less than 5-10% of 
mutations can be explained by these ‘core pathways’ in which a set of genes is relatively 
highly mutated [16, 17]. Several problems are associated with this approach. First, 
pathway gene members are fuzzy and poorly defined. For example, if different databases 
such as KEGG or BioCarta are queried for ‘EGFR signaling pathway,’ each database will 
provide a different gene list. Second, only a small set of mutation genes (less than 5-10%) 
can be mapped onto the ‘core pathways,’ thus, most mutation genes are unmapped. Third, 
for each study, only a few ‘core pathways’ such as RAS-PI3K were found repeatedly. 
These pathways are well known in cancer studies, and drugs have been developed for 
these pathways or key genes. In this respect, the pathway approach does not provide new 
insights but captures the existing knowledge in the field. 
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    To comprehensively understand the drivers of cancer genomes, computational methods 
should be developed because of the large number of driver mutation genes in each tumor. 
The development of effective computational methods first requires understanding what 
subjects biology addresses. Over many years, biologists have explored several types of 
relationships among genes, proteins, RNAs and other molecules. The molecular 
mechanisms of biological processes or diseases have also been studied. A molecular 
mechanism often discloses an event of A regulating B, B inducing or inhibiting C and 
generating a phenotype or disease. Each mechanism comprises a set of relationships 
between molecules such as gene regulation, protein interaction, activation, genetic 
interaction and inhibitory action. In this context, biology is a science that describes 
relationships [15].  
 
    Traditionally, biologists use pathways to describe the relationships between a limited 
number of genes. As shown above, numerous driver mutations have been found in each 
tumor, but the pathway approach explains only 5-10% of the genetic mutations in the 
cancer genome. It is expected that biologists must consider thousands of biological 
relationships with respect to these genes in one tumor, for which task the traditional 
methods of describing biological relationships are inadequate. Furthermore, as the cross-
talk between pathways has been documented extensively in recent years, scientists have 
come to recognize that a network model may provide a solution. A network model 
describes the interactions and relationships between genes or proteins in a nonlinear 
manner. The pathway and network approaches are conceptual models that reflect an 
avenue of exploring biology by humans. Both models project living cell molecules onto 
conceptual frameworks, but the molecular network model more closely approximates the 
processes that occur in cells. 
 
4.1. Basic concepts of molecular networks  
 
     A molecular network can be represented using nodes and links. Nodes represent genes 
or proteins, whereas links represent the relationships between genes and proteins. Cancer 
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omic data can be integrated into a molecular network to pose questions and obtain 
corresponding insights. However, different types of networks have distinct properties and 
thus can be used to address different questions. 
 
     There are four basic molecular networks: signaling, gene regulatory, metabolic and 
protein interaction networks. A network hub consists of the nodes that have the most 
links (top 5-10% of the links) within the network. However, a hub assumes a different 
biological meaning in different networks: hubs in gene regulatory networks represent 
global transcription factors, which assume a major role in responding to stimuli and 
coordinating the regulated genes. Consistent with this mechanism, the transcripts of the 
hub transcription factors often rapidly decay [18]. The rapidly decaying transcripts of 
global hub transcription factors might encode “switch” functions, which are used under 
different conditions and stimuli. Hubs in cellular signaling and metabolic networks help 
to organize information flows within the networks. Hubs in signaling networks assume a 
major role in integrating different signals and pathways [19]. However, hubs in protein 
interactions indicate that hub proteins are involved in considerably more biological 
processes/protein complexes than are other proteins [20]. 
 
     Most targets of transcription factors in regulatory networks are “workers.” They 
directly execute the tasks of biological processes. Most nodes in gene regulatory network 
have no regulatory role, whereas most nodes in cellular signaling networks have 
regulatory roles. In signaling networks, approximately all nodes are “regulators.” 
Therefore, logical regulatory relationships are extensively encoded in signaling networks. 
In another view, nodes in signaling networks are information carriers. Similarly, nodes in 
metabolic networks are carriers of the metabolic flux. Nodes in protein interaction 
networks are members of protein complexes, or ‘co-workers,’ that interact and 
collaborate to complete specific tasks. [15] 
 
    Generally, signaling networks contain several logical codes of regulation, whereas 
protein interaction networks do not encode regulatory logics. Gene regulatory networks 
encode both regulatory logic and gene “workers.” Gene regulatory networks help to 
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identify key cancer regulators, the co-expression of genes, and the sets of “workers” 
involved in cancer processes, whereas signaling networks help to identify cancer causal 
genes and the regulatory logic in cancer processes [15]. Protein interaction networks 
provide a source for identifying co-workers in cancer progression or metastasis [15]. In 
recent years, notable discoveries have also addressed cancer metabolism. For example, 
hypoxia and isocitrate dehydrogenase 1 (IDH1) function in the citric acid cycle pathway, 
an energy-generating pathway. The IDH1 mutations cause the accumulation of 2-
hydroxyglutarate, a metabolite in the metabolic pathway, and thus cause cancer [21] [22, 
23]. These studies generate interest in studying cancer in metabolic networks. Metabolic 
networks could help identify key enzymes or metabolites that could induce metabolic 
chaos and thus cause cancer. 
 
     When incorporating cancer omic data into these networks, the expression levels of 
major regulators (i.e., kinases) in signaling networks do not necessarily change 
dramatically during cancer progression and metastasis because signaling cascades are 
modulated through protein modifications, not gene regulation. Indeed, examining 
phosphoproteomic data in signaling networks is informative [24].  
 
4.2. An integrative network analysis of cancer omic data  
 
    Prior to the advent of cancer genome sequencing, researchers pursued network 
analyses of cancer-related data. Additional details regarding this research are available in 
reviews [25, 26] and in the book Cancer Systems Biology [15]. For example, an 
integrative analysis of tumor gene expression profiles and protein interaction networks 
permits the identification of network modules as cancer biomarkers. A network module 
contains a set of closely interacted genes/proteins that collaborate to perform certain 
biological process. In a network module, the interactions between the module members 
are more frequent than the interactions between the module members with the 
protein/nodes outside the module. The resulting network module markers are more 
reproducible than traditionally obtained biomarkers that are identified without using 
protein interaction networks [27, 28].  
 14 
 
     Another study found that the protein network modules of gene co-expression are more 
reliable predictors than the biomarkers that are identified without considering network 
modules [29]. Exhaustively describing human molecular networks is a long-term task. 
Therefore, although the network module approach has yielded promising results, the 
accuracy of its predictions is nevertheless low (less than 80%). However, excellent results 
(i.e., over 90% prediction accuracy when tested in multiple independent patient cohorts) 
have been obtained with biomarkers through cancer-hallmark-based functional modules 
that extend beyond the network module [30].  
 
     A functional module biomarker is linked to a network module of cancer driver-
mutating genes on the protein interaction network. Notably, as long as the genes, which 
perform the same function of the module and act as the interacting partners of proteins in 
the cancer-driver network module, are modulated, they show predictive power (Figure 2) 
[30]. Most importantly, the members of the cancer-driver network module are fixed, but 
the modules’ modulated interacting partners change with patient cohorts [30]. These 
results explain why many potential biomarker sets exhibit limited overlap, a well-known 
phenomenon in the cancer biomarker field. 
 
     The first study that attempted to interpret the drivers behind cancer-mutating genes in 
networks was published in 2007. In this work, Cui et al. [31] first examined the 
traditionally discovered cancer-mutating genes, which were considered to be cancer 
drivers and which were mined using the COSMIC database, using a manually curated 
human signaling network. They identified 12 cancer signaling network modules in which 
cancer-mutating genes were densely connected. Such modules cannot be discovered 
using a pathway approach or by examining mutating genes individually. Cui et al. applied 
these modules to the drivers behind the mutating genes derived from the first genome-
wide sequencing of cancer [32] and found that these mutations became meaningful if 
assigned to 2 or 3 signaling network modules [31].  
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     This result resolved the controversial arguments concerning whether tumor genome 
sequencing should continue [33] because the first study of tumor genome sequencing 
showed that cancer mutations are highly complex: driver-mutating genes are rare, even in 
the tumors of sample origin, such as breast cancer [34]. In addition, these genes are not 
organized into pathways. Subsequently, some scientists argued that cancer genome 
sequencing is time- and resource-consuming and provides unclear results [33]. Cui et 
al.’s network analysis provides evidence that cancer driver-mutating genes are organized 
into network modules to assume roles. Lincoln Stein and colleagues [35] used an 
extended signaling network to examine cancer driver-mutating genes derived from the 
genome sequencing of two glioblastoma multiforme data sets [17, 36] and confirmed that 
cancer driver-mutating genes are organized into network modules. 
 
    Given that current networks are incomplete, Ciriello et al. [37] used correlation 
analysis and statistical approaches to develop a method for identifying cancer gene 
modules, specifically, Mutual Exclusivity Modules in cancer (MEMo). MEMo considers 
the frequency of cancer gene mutation across a set of tumor samples. Cancer mutation 
genes are most likely to participate in the same biological process, and cancer-mutating 
genes that are involved in the same biological process are mutually exclusive in a 
module. This approach may help detect cancer gene modules that cannot be found with 
existing networks. However, a limitation of the method is that the sample number 
significantly affects the results. 
 
     Akavia et al. [38] used a Bayesian network approach to develop a network-module-
based method, CONEXIC (computational algorithm, copy number and expression in 
cancer) to examine DNA copy number alterations in tumor genomes. This approach 
integrates copy number alterations and gene expression profiles to identify potential 
cancer driver genes that have recurrent copy number changes in tumor samples. A 
limitation of this study is that the Bayesian network learning approach and other network 
learning approaches exhibit weak performance for eukaryotic genomes, such as those in 
yeast and humans [39].  
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5. Future directions 
 
    An integrative network analysis of cancer genome sequencing data is in its early 
phases. Several challenges and questions need to be addressed. First, in terms of their 
functional importance, the cancer driver-mutating genes need to be prioritized into 
categories such as cancer cell survival or metastasis. This task is urgent because each 
tumor contains several hundred cancer driver-mutating genes, but it is unclear which 
genes should be prioritized in research. New network methods can be developed to 
answer this question. Second, the network of cancer stems cells requires further study to 
understand which combinations of mutating genes or epigenetic/copy number changes 
maintain the characteristics of cancer stems cells. Third, the network dynamics of cancer 
evolution should be mapped, and the key events that lead to cancer initiation need to be 
understood. Fourth, the networks of cancer hallmarks should be modeled. This approach 
has been proposed, and its necessity has been detailed in the book Cancer Systems 
Biology [15]. Li et al. obtained excellent results in identifying cancer biomarkers by 
modeling functional modules of cancer hallmarks [30]. Fu et al. also showed that 
apoptotic network motif modeling based one of the cancer hallmarks inferred that the 26S 
proteasome may help predict cancer prognosis [40]. Fifth, the dynamics of the cancer 
gene network motifs need to be studied, and the regulatory principles and controls of the 
oncogenic signaling information flows should be understood. In-depth discussions are 
available in a recent review [26]. Finally, new network algorithms need to be developed 
to translate some cancer mutations and other genetic/epigenetic changes into drug targets. 
Inarguably, many other problems and activities may be solved through an integrative 
network approach. With additional cancer high-throughput studies in the near future, we 
believe that the integrative network approach will become increasingly useful to cancer 
research. 
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Figure Legends 
 
Fig. 1. A hypothesis of a stem cell-based cancer genome evolution. The production of a 
cancer stem cell requires a long time (5-10 years) and a series of changes with respect to 
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somatic mutations, copy number variations and epigenetic factors from a normal cell. The 
cancer stem cell generates cancer cells. Some mutations or copy number changes could 
lead one cancer cell derived from the cancer stem cell to acquire significant growth 
advantages. This cancer cell will propagate to dominate the tumor and eventually make 
the tumor clinically detectable. 
 
 
Fig. 2. Stable cancer driver-mutating gene modules have predictive power in cancer 
prognosis. The content of this figure was developed from a cancer prognostic gene 
signature derived from Li et al. [30]. For example, this gene signature represents 
apoptosis, one of the cancer hallmarks. A driver-module is formed by collecting the 
genes (blue) that are the interacting neighbors of the signature genes (brown). By 
obtaining microarray gene expression profiles from a breast cancer cohort, we obtained 
modulated genes between recurred and non-recurred tumors. We sought a predictive gene 
signature by collecting the genes (green) that are not only the interacting neighbors of the 
driver-module genes (blue), but also the modulated genes sharing the same function with 
the original gene signature (i.e., apoptosis). We found that the predictive gene signature 
(green genes) has predictive power for prognosis. It is notable that another set of the 
predictive gene signature (green genes) can be obtained when changing patient cohorts. 
However, the new genes in green maintain their predictive power. These results explain 
the phenomenon that the gene sets of different cancer biomarkers for an identical cancer 
type rarely overlap. More detailed explanations are in Li et al. [30]. Protein interaction 
networks contain circles (nodes) and solid lines that represent genes and their 
interactions, respectively. Brown, blue and green nodes represent signature genes, breast 
cancer driver-mutating genes, and breast cancer modulated genes, respectively, between 
recurred and non-recurred tumors. Dotted lines represent the signature genes mapped to 
the genes in the network. 
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Table 1. A list of major completed tumor genome sequencing projects.  
 
Tumor type Number of 
tumors 
sequenced 
Year  Reference 
Lung cancer 31 2012 [41] 
Lung cancer 53 2012 [42] 
Lung cancer 183 2012 [43] 
Lung cancer 178 2012 [44] 
Breast cancer  825 2012 [45] 
Breast cancer 125 2012 [46] 
Breast cancer 77 2012 [47] 
Breast cancer 21 2012 [7] 
Breast cancer 100 2012 [48] 
Breast cancer 65 2012 [49] 
Breast cancer 11 2006 [50] 
Medulloblastoma 37 2012 [51] 
Medulloblastoma 92 2012 [52] 
Medulloblastoma 125 2012 [53] 
Acute myeloid leukemia 24 2012 [54] 
Multiple myeloma 38 2011 [55] 
Chronic lymphocytic 
leukemia 
105 2012 [56] 
Melanoma 121 2012 [57] 
Melanoma 25 2012 [58] 
Prostate cancer 112 2012 [59] 
Prostate cancer 50 2012 [60] 
Prostate cancer 23 2011 [61] 
Colon and rectal cancer 224 2012 [62] 
Colon cancer  11 2006 [50] 
Liver cancer 27 2012 [63] 
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Hepatocellular carcinoma 24 2012 [64] 
Diffuse large B-cell 
lymphoma 
55 2012 [65] 
Pediatric glioblastoma 48 2012 [66] 
Gastric cancer 22 2011 [67] 
Ovarian carcinoma 316 2011 [68] 
Head and neck carcinoma 74 2011 [69] 
Head and neck carcinoma 32 2011 [70] 
Note: Projects that have sequenced more than 20 cancer genomes at an exome or an 
entire genome level have been selected. The majority of the work was published in 2012.  
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